204 related articles for article (PubMed ID: 33116484)
61. Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine.
Khan I; Gothwal A; Sharma AK; Qayum A; Singh SK; Gupta U
Int J Biol Macromol; 2016 Nov; 92():1242-1251. PubMed ID: 27527691
[TBL] [Abstract][Full Text] [Related]
62. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit
Naeem M; Bae J; Oshi MA; Kim MS; Moon HR; Lee BL; Im E; Jung Y; Yoo JW
Int J Nanomedicine; 2018; 13():1225-1240. PubMed ID: 29535519
[TBL] [Abstract][Full Text] [Related]
63. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization.
Parumasivam T; Leung SS; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Sci; 2016 Jun; 88():1-11. PubMed ID: 27049049
[TBL] [Abstract][Full Text] [Related]
64. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
Carneiro SP; Carvalho KV; de Oliveira Aguiar Soares RD; Carneiro CM; de Andrade MHG; Duarte RS; Dos Santos ODH
Colloids Surf B Biointerfaces; 2019 Mar; 175():306-313. PubMed ID: 30553206
[TBL] [Abstract][Full Text] [Related]
65. Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules.
Giovino C; Ayensu I; Tetteh J; Boateng JS
Int J Pharm; 2012 May; 428(1-2):143-51. PubMed ID: 22405987
[TBL] [Abstract][Full Text] [Related]
66. Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery.
Gupta M; Chashoo G; Sharma PR; Saxena AK; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2014 Mar; 11(3):697-715. PubMed ID: 24512060
[TBL] [Abstract][Full Text] [Related]
67. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
[TBL] [Abstract][Full Text] [Related]
68. Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations.
Hu X; Yang F; Liao Y; Li L; Zhang L
Drug Deliv; 2017 Nov; 24(1):121-132. PubMed ID: 28156159
[TBL] [Abstract][Full Text] [Related]
69. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.
Dawson R; Narunsky K; Carman D; Gupte N; Whitelaw A; Efron A; Barnes GL; Hoffman J; Chaisson RE; McIlleron H; Dorman SE
Int J Tuberc Lung Dis; 2015 Jul; 19(7):780-6. PubMed ID: 26056101
[TBL] [Abstract][Full Text] [Related]
70. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
71. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
72. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
Mistry NP; Desai JL; Thakkar HP
J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
[TBL] [Abstract][Full Text] [Related]
73. Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin.
Samkange T; D'Souza S; Obikeze K; Dube A
J Pharm Pharmacol; 2019 Oct; 71(10):1497-1507. PubMed ID: 31385295
[TBL] [Abstract][Full Text] [Related]
74. Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles.
Yadav KS; Chuttani K; Mishra AK; Sawant KK
PDA J Pharm Sci Technol; 2011; 65(2):131-9. PubMed ID: 21502074
[TBL] [Abstract][Full Text] [Related]
75. Microfluidic nanoprecipitation of PEGylated PLGA nanoparticles with rapamycin and performance evaluation.
Guo J; Dai W; Wu W; Zhuang S; Zhang H; Cen L
J Biomater Sci Polym Ed; 2024 Jun; 35(8):1197-1213. PubMed ID: 38421916
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
Xin L; Zhang HT; Yang WF; Li YF; Liu C
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29229675
[TBL] [Abstract][Full Text] [Related]
77. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
78. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
[TBL] [Abstract][Full Text] [Related]
79. Lactose-Conjugated PLGA Nanoparticles for Enhanced Delivery of Rifampicin to the Lung for Effective Treatment of Pulmonary Tuberculosis.
Jain SK; Gupta Y; Ramalingam L; Jain A; Jain A; Khare P; Bhargava D
PDA J Pharm Sci Technol; 2010; 64(3):278-87. PubMed ID: 21502027
[TBL] [Abstract][Full Text] [Related]
80. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
